RespireRx Pharmaceuticals Inc. (RSPI)
USD 0.0
(15.0%)
USD 0.0
(15.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 11.9 Million USD | 16.51% |
| 2021 | 10.21 Million USD | 25.38% |
| 2020 | 8.14 Million USD | 8.79% |
| 2019 | 7.49 Million USD | 27.87% |
| 2018 | 5.85 Million USD | 28.73% |
| 2017 | 4.55 Million USD | -20.55% |
| 2016 | 5.72 Million USD | 90.4% |
| 2015 | 3 Million USD | 15.66% |
| 2014 | 2.6 Million USD | -38.67% |
| 2013 | 4.24 Million USD | 32.91% |
| 2012 | 3.19 Million USD | 178.7% |
| 2011 | 1.14 Million USD | -1.65% |
| 2010 | 1.16 Million USD | -47.89% |
| 2009 | 2.23 Million USD | 27.23% |
| 2008 | 1.75 Million USD | 0.22% |
| 2007 | 1.75 Million USD | -17.15% |
| 2006 | 2.11 Million USD | -25.98% |
| 2005 | 2.85 Million USD | -54.41% |
| 2004 | 6.26 Million USD | 74.08% |
| 2003 | 3.59 Million USD | 0.75% |
| 2002 | 3.57 Million USD | -34.09% |
| 2001 | 5.42 Million USD | 377.67% |
| 2000 | 1.13 Million USD | -33.73% |
| 1999 | 1.71 Million USD | -56.16% |
| 1998 | 3.9 Million USD | 126.0% |
| 1997 | 1.72 Million USD | 26.23% |
| 1996 | 1.36 Million USD | -14.43% |
| 1995 | 1.6 Million USD | 128.57% |
| 1994 | 700 Thousand USD | 133.33% |
| 1993 | 300 Thousand USD | -62.5% |
| 1992 | 800 Thousand USD | -75.0% |
| 1991 | 3.2 Million USD | 128.57% |
| 1990 | 1.4 Million USD | -22.22% |
| 1989 | 1.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 12.4 Million USD | 4.23% |
| 2023 Q2 | 12.28 Million USD | -0.99% |
| 2023 Q3 | 12.4 Million USD | 0.99% |
| 2022 Q1 | 10.97 Million USD | 7.39% |
| 2022 FY | 11.9 Million USD | 16.51% |
| 2022 Q4 | 11.9 Million USD | 2.25% |
| 2022 Q3 | 11.64 Million USD | 3.85% |
| 2022 Q2 | 11.2 Million USD | 2.17% |
| 2021 FY | 10.21 Million USD | 25.38% |
| 2021 Q4 | 10.21 Million USD | 5.82% |
| 2021 Q1 | 8.56 Million USD | 5.05% |
| 2021 Q3 | 9.65 Million USD | 7.76% |
| 2021 Q2 | 8.95 Million USD | 4.66% |
| 2020 Q1 | 7.55 Million USD | 0.82% |
| 2020 Q3 | 7.34 Million USD | -7.41% |
| 2020 Q4 | 8.14 Million USD | 10.95% |
| 2020 FY | 8.14 Million USD | 8.79% |
| 2020 Q2 | 7.93 Million USD | 5.04% |
| 2019 FY | 7.49 Million USD | 27.87% |
| 2019 Q3 | 7.14 Million USD | 5.6% |
| 2019 Q1 | 6.37 Million USD | 8.79% |
| 2019 Q2 | 6.76 Million USD | 6.19% |
| 2019 Q4 | 7.49 Million USD | 4.81% |
| 2018 Q2 | 5.21 Million USD | 1.37% |
| 2018 Q1 | 5.14 Million USD | 12.99% |
| 2018 Q4 | 5.85 Million USD | 5.3% |
| 2018 Q3 | 5.56 Million USD | 6.73% |
| 2018 FY | 5.85 Million USD | 28.73% |
| 2017 Q4 | 4.55 Million USD | -34.53% |
| 2017 FY | 4.55 Million USD | -20.55% |
| 2017 Q3 | 6.94 Million USD | 6.92% |
| 2017 Q2 | 6.5 Million USD | 2.8% |
| 2017 Q1 | 6.32 Million USD | 10.4% |
| 2016 Q1 | 3.92 Million USD | 30.35% |
| 2016 Q4 | 5.72 Million USD | 13.48% |
| 2016 FY | 5.72 Million USD | 90.4% |
| 2016 Q3 | 5.04 Million USD | 18.13% |
| 2016 Q2 | 4.27 Million USD | 8.96% |
| 2015 Q4 | 3 Million USD | 15.11% |
| 2015 Q2 | 2.8 Million USD | -2.41% |
| 2015 Q1 | 2.87 Million USD | 10.49% |
| 2015 FY | 3 Million USD | 15.66% |
| 2015 Q3 | 2.61 Million USD | -6.81% |
| 2014 Q4 | 2.6 Million USD | 12.38% |
| 2014 FY | 2.6 Million USD | -38.67% |
| 2014 Q1 | 2.89 Million USD | -31.67% |
| 2014 Q3 | 2.31 Million USD | -8.01% |
| 2014 Q2 | 2.51 Million USD | -13.16% |
| 2013 Q4 | 4.24 Million USD | 2.46% |
| 2013 Q2 | 4.06 Million USD | 2.48% |
| 2013 Q1 | 3.96 Million USD | 24.26% |
| 2013 FY | 4.24 Million USD | 32.91% |
| 2013 Q3 | 4.13 Million USD | 1.87% |
| 2012 Q4 | 3.19 Million USD | 13.53% |
| 2012 Q3 | 2.81 Million USD | 60.3% |
| 2012 Q2 | 1.75 Million USD | 46.97% |
| 2012 Q1 | 1.19 Million USD | 4.19% |
| 2012 FY | 3.19 Million USD | 178.7% |
| 2011 Q1 | 1.23 Million USD | 6.51% |
| 2011 Q2 | 1.23 Million USD | -0.05% |
| 2011 Q4 | 1.14 Million USD | -13.54% |
| 2011 Q3 | 1.32 Million USD | 6.85% |
| 2011 FY | 1.14 Million USD | -1.65% |
| 2010 FY | 1.16 Million USD | -47.89% |
| 2010 Q4 | 1.16 Million USD | -24.17% |
| 2010 Q3 | 1.53 Million USD | -14.4% |
| 2010 Q2 | 1.79 Million USD | -56.7% |
| 2010 Q1 | 4.14 Million USD | 85.43% |
| 2009 Q2 | 2.14 Million USD | -13.76% |
| 2009 FY | 2.23 Million USD | 27.23% |
| 2009 Q1 | 2.48 Million USD | 41.52% |
| 2009 Q4 | 2.23 Million USD | 17.99% |
| 2009 Q3 | 1.89 Million USD | -11.65% |
| 2008 Q3 | 1.86 Million USD | -26.41% |
| 2008 Q4 | 1.75 Million USD | -5.93% |
| 2008 FY | 1.75 Million USD | 0.22% |
| 2008 Q1 | 2.5 Million USD | 43.23% |
| 2008 Q2 | 2.53 Million USD | 1.08% |
| 2007 Q4 | 1.75 Million USD | -16.04% |
| 2007 Q1 | 1.64 Million USD | -22.04% |
| 2007 FY | 1.75 Million USD | -17.15% |
| 2007 Q2 | 1.72 Million USD | 4.92% |
| 2007 Q3 | 2.08 Million USD | 20.63% |
| 2006 FY | 2.11 Million USD | -25.98% |
| 2006 Q3 | 2.26 Million USD | -9.23% |
| 2006 Q2 | 2.49 Million USD | 6.23% |
| 2006 Q1 | 2.35 Million USD | -17.72% |
| 2006 Q4 | 2.11 Million USD | -6.7% |
| 2005 Q4 | 2.85 Million USD | 39.11% |
| 2005 Q3 | 2.05 Million USD | 1.41% |
| 2005 Q1 | 2.4 Million USD | -99.96% |
| 2005 Q2 | 2.02 Million USD | -15.71% |
| 2005 FY | 2.85 Million USD | -54.41% |
| 2004 Q2 | 2.4 Million USD | 33.16% |
| 2004 FY | 6.26 Million USD | 74.08% |
| 2004 Q1 | 1.8 Million USD | -32.6% |
| 2004 Q3 | 1.7 Million USD | -28.88% |
| 2004 Q4 | 6.26 Billion USD | 366679.82% |
| 2003 Q3 | 2.16 Million USD | -39.93% |
| 2003 Q2 | 3.59 Million USD | 41.82% |
| 2003 Q4 | 2.67 Million USD | 23.76% |
| 2003 FY | 3.59 Million USD | 0.75% |
| 2003 Q1 | 2.53 Million USD | -9.23% |
| 2002 Q1 | 4.09 Million USD | 6.3% |
| 2002 FY | 3.57 Million USD | -34.09% |
| 2002 Q4 | 2.79 Million USD | -24.08% |
| 2002 Q3 | 3.68 Million USD | 3.09% |
| 2002 Q2 | 3.57 Million USD | -12.76% |
| 2001 Q3 | 4.7 Million USD | -13.17% |
| 2001 Q1 | 5.22 Million USD | -10.28% |
| 2001 FY | 5.42 Million USD | 377.67% |
| 2001 Q2 | 5.42 Million USD | 3.82% |
| 2001 Q4 | 3.85 Million USD | -18.14% |
| 2000 Q1 | 790.86 Thousand USD | -43.24% |
| 2000 FY | 1.13 Million USD | -33.73% |
| 2000 Q4 | 5.81 Million USD | 220.47% |
| 2000 Q3 | 1.81 Million USD | 60.02% |
| 2000 Q2 | 1.13 Million USD | 43.48% |
| 1999 Q3 | 1.3 Million USD | -23.5% |
| 1999 Q1 | 1.77 Million USD | 10.63% |
| 1999 FY | 1.71 Million USD | -56.16% |
| 1999 Q4 | 1.39 Million USD | 6.52% |
| 1999 Q2 | 1.71 Million USD | -3.39% |
| 1998 Q1 | 1.5 Million USD | 0.0% |
| 1998 Q4 | 1.6 Million USD | 6.67% |
| 1998 Q3 | 1.5 Million USD | -61.6% |
| 1998 FY | 3.9 Million USD | 126.0% |
| 1998 Q2 | 3.9 Million USD | 160.4% |
| 1997 Q4 | 1.5 Million USD | 0.0% |
| 1997 FY | 1.72 Million USD | 26.23% |
| 1997 Q1 | 1.4 Million USD | -6.67% |
| 1997 Q2 | 1.72 Million USD | 23.45% |
| 1997 Q3 | 1.5 Million USD | -13.21% |
| 1996 Q3 | 1.3 Million USD | -5.05% |
| 1996 Q4 | 1.5 Million USD | 15.38% |
| 1996 Q2 | 1.36 Million USD | 5.32% |
| 1996 Q1 | 1.3 Million USD | 0.0% |
| 1996 FY | 1.36 Million USD | -14.43% |
| 1995 Q3 | 1.5 Million USD | -6.25% |
| 1995 Q4 | 1.3 Million USD | -13.33% |
| 1995 FY | 1.6 Million USD | 128.57% |
| 1995 Q1 | 300 Thousand USD | -40.0% |
| 1995 Q2 | 1.6 Million USD | 433.33% |
| 1994 Q4 | 500 Thousand USD | -16.67% |
| 1994 Q1 | 900 Thousand USD | 143.24% |
| 1994 Q2 | 700 Thousand USD | -22.22% |
| 1994 Q3 | 600 Thousand USD | -14.29% |
| 1994 FY | 700 Thousand USD | 133.33% |
| 1993 Q3 | 420 Thousand USD | 40.0% |
| 1993 Q1 | 800 Thousand USD | -3.61% |
| 1993 Q4 | 370 Thousand USD | -11.9% |
| 1993 FY | 300 Thousand USD | -62.5% |
| 1993 Q2 | 300 Thousand USD | -62.5% |
| 1992 Q2 | 800 Thousand USD | 135.29% |
| 1992 Q3 | 340 Thousand USD | -57.5% |
| 1992 FY | 800 Thousand USD | -75.0% |
| 1992 Q4 | 830 Thousand USD | 144.12% |
| 1992 Q1 | 340 Thousand USD | 9.68% |
| 1991 Q3 | 300 Thousand USD | -90.63% |
| 1991 Q4 | 310 Thousand USD | 3.33% |
| 1991 FY | 3.2 Million USD | 128.57% |
| 1991 Q1 | 250 Thousand USD | 8.7% |
| 1991 Q2 | 3.2 Million USD | 1180.0% |
| 1990 Q3 | 280 Thousand USD | -80.0% |
| 1990 FY | 1.4 Million USD | -22.22% |
| 1990 Q1 | 90 Thousand USD | -30.77% |
| 1990 Q2 | 1.4 Million USD | 1455.56% |
| 1990 Q4 | 230 Thousand USD | -17.86% |
| 1989 Q3 | 170 Thousand USD | -90.56% |
| 1989 Q2 | 1.8 Million USD | 0.0% |
| 1989 Q4 | 130 Thousand USD | -23.53% |
| 1989 FY | 1.8 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -43289.717% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -25.747% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 83.575% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1371.71% |
| Rebus Holdings, Inc. | 5.24 Million USD | -127.072% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 79.83% |
| Qrons Inc. | 1.48 Million USD | -699.556% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -870.721% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 84.112% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -26531.244% |
| Skye Bioscience, Inc. | 14.07 Million USD | 15.414% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 77.67% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -24.223% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2723.53% |
| SQZ Biotechnologies Company | 50.03 Million USD | 76.212% |
| Intellipharmaceutics International Inc. | 12 Million USD | 0.88% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -209.057% |
| Mesoblast Limited | 188.44 Million USD | 93.684% |
| Marizyme, Inc. | 26.67 Million USD | 55.379% |
| Genus plc | 485 Million USD | 97.546% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -103.729% |
| Pharming Group N.V. | 244.07 Million USD | 95.123% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -492.156% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -373.035% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -213.24% |
| ContraFect Corporation | 32.53 Million USD | 63.41% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -500.77% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -210.977% |
| IMV Inc. | 37.93 Million USD | 68.621% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1.06% |
| MultiCell Technologies, Inc. | 1617.67 USD | -735717.627% |
| ONE Bio Corp. | 27.49 Million USD | 56.709% |
| Accustem Sciences Inc. | 1.07 Million USD | -1002.916% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 84.625% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -462.776% |
| Q BioMed Inc. | 8.13 Million USD | -46.357% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 85.648% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -131.306% |
| Biomind Labs Inc. | 1.49 Million USD | -694.275% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 89.974% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -31.64% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 35.321% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -730.143% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -8276.861% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -5818.525% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -107.161% |
| GB Sciences, Inc. | 5.41 Million USD | -119.713% |
| Alpha Cognition Inc. | 7.16 Million USD | -66.134% |
| HST Global, Inc. | 593.59 Thousand USD | -1905.263% |
| CSL Limited | 18.62 Billion USD | 99.936% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -845.296% |
| Halberd Corporation | 728.71 Thousand USD | -1533.428% |
| Enzolytics Inc. | 365.26 Million USD | 96.741% |
| Agentix Corp. | 2.51 Million USD | -374.122% |
| Resverlogix Corp. | 67.39 Million USD | 82.339% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1319.178% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.325% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -594.463% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 51.899% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -224.763% |
| AVAX Technologies, Inc. | 3.99 Million USD | -198.044% |
| Zenith Capital Corp. | 27.56 Thousand USD | -43075.672% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.102% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4887.598% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -218.75% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1648.312% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -338.963% |
| Kadimastem Ltd | 3.5 Million USD | -239.616% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -17684.669% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 76.319% |
| BioStem Technologies, Inc. | 15.9 Million USD | 25.16% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2461.465% |
| LadRx Corporation | 2.2 Million USD | -440.92% |
| Cell Source, Inc. | 15.8 Million USD | 24.696% |
| Regen BioPharma, Inc. | 5.45 Million USD | -118.101% |
| Regen BioPharma, Inc. | 5.45 Million USD | -118.101% |
| NovAccess Global Inc. | 7.86 Million USD | -51.425% |
| Affymax, Inc. | 8.87 Million USD | -34.18% |
| Itoco Inc. | 1.65 Million USD | -620.025% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -480.196% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -96.778% |
| Mobile Lads Corp. | 1.31 Million USD | -806.215% |
| CytoDyn Inc. | 127.89 Million USD | 90.693% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -28376.999% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -659.913% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -7.766% |
| SYBLEU INC | 681.41 Thousand USD | -1646.826% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -95.072% |
| International Stem Cell Corporation | 5.27 Million USD | -125.566% |
| Bioxytran, Inc. | 3.24 Million USD | -266.306% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1802.034% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -157.803% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 70.965% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 46.539% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -487.695% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -117.289% |
| Neutra Corp. | 973.52 Thousand USD | -1122.676% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 58.976% |
| PureTech Health plc | 125.58 Million USD | 90.522% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -216.814% |
| IXICO plc | 1.9 Million USD | -526.383% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 42.018% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 88.48% |
| CSL Limited | 18.62 Billion USD | 99.936% |
| Cellectis S.A. | 249.36 Million USD | 95.227% |